Page last updated: 2024-12-11

bms 806

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5495818
CHEMBL ID337301
SCHEMBL ID1288198
MeSH IDM0420445

Synonyms (46)

Synonym
HY-14134
1-[(2r)-4-benzoyl-2-methyl-piperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione
bms 378806
bms-377806
357263-13-9
bms-378806
piperazine, 4-benzoyl-1-[2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)-1,2-dioxoethyl]-2-methyl-, (2r)-
bms-806
bms-378806 & pro 140
piperazine, 4-benzoyl-1-[2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)-1,2-dioxoethyl]-2-methyl-, (2r)- & pro 140 (anti-ccr5 monoclonal antibody)
bms 806
4-benzoyl-1-[(4-methoxy-1hpyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(r)-methylpiperazine
bdbm50133282
(r)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione
1-((r)-4-benzoyl-2-methyl-piperazin-1-yl)-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)-ethane-1,2-dione
CHEMBL337301 ,
1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione
4-benzoyl-1-((4-methoxy-1h- pyrrolo(2,3-b)pyridin-3-yl)oxoacetyl)-2- (r)-methylpiperazine
bmx 806
piperazine, 4-benzoyl-1-(2-(4-methoxy-1h-pyrrolo(2,3-b)pyridin-3-yl)-1,2-dioxoethyl)-2-methyl-, (2r)-
unii-imn5e6pluk
imn5e6pluk ,
BCP9000438
AKOS015966753
bms378806
BMS806 ,
BCP0726000252
CS-0525
S2632
1,2-ethanedione, 1-((2r)-4-benzoyl-2-methyl-1-piperazinyl)-2-(4-methoxy-1h-pyrrolo(2,3-b)pyridin-3-yl)-
piperazine, 4-benzoyl-1-((4-methoxy-1h-pyrrolo(2,3-b)pyridin-3-yl)oxoacetyl)-2-methyl-, (2r)-
(-)-bms-378806
SCHEMBL1288198
sinova sl-02580
bms-806 (bms 378806)
83g ,
1-[(2r)-4-(benzenecarbonyl)-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione
SW219865-1
EX-A2556
bms-378806; bms-806
4-benzoyl-1-[(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(r)-methylpiperazine
CCG-268720
Q27280796
F84307
AC-36135
AS-77845

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" BMS-378806 displays many favorable pharmacological traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicology studies."( A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
Blair, W; Colonno, R; Demers, G; Deminie, C; Fridell, R; Gong, YF; Guo, Q; Li, CB; Lin, PF; Meanwell, N; Robinson, B; Rose, R; Spicer, T; Wang, HG; Wang, T; Yamanaka, G; Yang, Z; Zadjura, L; Zhou, N, 2003
)
0.32
" BMS-378806 exhibits no significant cytotoxicity and displays many attractive pharmacological properties such as low protein binding, minimal serum effect on anti-HIV-1 potency, good oral bioavailability in animal species and a clean safety profile in initial animal toxicology studies."( A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
Lin, PF; Wang, HG; Williams, RE, 2004
)
0.32
" BMS-378806 exhibited species-dependent oral bioavailability which was 19%-24% in rats and monkeys and 77% in dogs."( Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Colonno, R; D'Arienzo, C; Greene, D; Hansel, S; Klunk, L; Lin, PF; Marino, A; Meanwell, N; Santone, K; Wang, T; Yang, Z; Zadjura, L, 2005
)
0.33
" Particularly, BMS-378806 and its derivatives are newly identified class of orally bioavailable HIV-1 inhibitors that interfere gp120-CD4 interaction."( Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
De Clercq, E; Huang, B; Liu, T; Liu, X; Zhan, P, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
"Antiviral efficacy of DS003 was assessed in mucosal tissue explants (ecto-cervical, penile and colorectal) and in trans-infection models (co-cultures of dendritic or mucosal migratory cells with CD4+ T cells) with several dosing times (2, 24 h and sustained) and in combination with a fusion inhibitor."( The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate.
Aldon, Y; Armanasco, N; Harman, S; Herrera, C; Nuttall, J; Rogers, P; Shattock, RJ; Stieh, D; Ziprin, P, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)40.00000.00011.774010.0000AID446491
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)40.00000.00011.753610.0000AID446486; AID446487
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)9.70000.00002.015110.0000AID446489
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)40.00000.00002.800510.0000AID446488
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)40.00000.00002.398310.0000AID446490
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)80.00000.00091.901410.0000AID446493
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Human immunodeficiency virus 1IC50 (µMol)8.70000.00352.70228.7000AID1525493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (100)

Assay IDTitleYearJournalArticle
AID421174Antiviral activity against HIV isolate 584.000 054 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID209543Inhibitory activity of compound against TLAV (dual) virus that utilizes both CXR4 and CCR5 co-receptor virus was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID421170Cytotoxicity against human U87 cells coexpressing CD4, CxCR4 receptors after 72 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID1295691Antiviral activity against HIV1 3B infected in MT2 cells assessed as reduction cell viability2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
AID446488Inhibition of recombinant CYP2C92009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID200784Inhibitory activity of compound against SF-162 (M) Macrophage tropic virus that utilizes the CCR5 was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID304732Antiviral activity against HIV 584.000088 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID392513Antiviral activity against HIV12009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID304733Antiviral activity against HIV 584.000241 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID446490Inhibition of recombinant CYP2C192009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID446494Oral bioavailability in dog at 5 mg/kg2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID446496Cmax in rat at 5 mg/kg, po2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304729Antiviral activity against HIV 584.000030 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID28506The maximum plasma concentration of compound after paroral administration of 3.4(mg/kg) polyethelene glycol in monkey was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID725040Antiviral activity against HIV1 JR-FL in human HeLa cells expressing CD4, CCR5 assessed as inhibition of integration of viral DNA into cell genome after 3 days by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
AID421168Antiviral activity against HIV1 expressed in 293T cells assessed as protection against viral M33 envelope infection in human U87 cells coexpressing CD4, CCR5 receptors after 72 hrs by luciferase reporter gene pseudoviral assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID99945Cytotoxicity activity of compound in MT-2 cells against LAI (T) tropic virus that utilizes the CXCR-4 co-receptor virus was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID1454914Dissociation constant, pKa of the compound2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID23935The total clearance time in dog was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID421172Antiviral activity against HIV isolate 584.000 030 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID99946Inhibitory activity of compound against LAI (T) tropic virus that utilizes the CXCR-4 co-receptor was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID446479Inhibition of HIV1 JRFL gp120/CD4 interaction in human HeLa67 cells assessed as inhibition of viral entry after 3 days by luciferase reporter gene assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID427794Inhibition of HIV1 (isolate YU2) envelope glycoprotein 120-mediated membrane fusion between virus-transfected african green monkey COS cells and human TZM-bl cells by luciferase-based cell-cell fusion assay in presence of IC95642008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
AID1872005Antiviral activity against laboratory-adapted HIV-1 NL4-3 infected in human TZM-bl cells incubated for 2 days by luciferase based analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID421173Antiviral activity against HIV isolate 584.000 031 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID28507The maximum plasma concentration of compound after paroral administration of 5(mg/kg) polyethelene glycol in rat was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID304725Antiviral activity against HIV 589.000049 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID446498Terminal half life in rat at 5 mg/kg, iv2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID421178Antiviral activity against HIV isolate 584.000.098 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID200786Inhibitory activity of compound against SF-2 (T) tropic virus that utilizes the CXCR-4 co-receptor was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID1525492Antiviral activity against HIV1 3B infected in human MT2 cells incubated for 5 days by MTT assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Overview of Recent Strategic Advances in Medicinal Chemistry.
AID30150The volume of distribution of compound was determined in monkey2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID725038AUC in rat at 5 mg/kg, po2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
AID304730Antiviral activity against HIV 584.000039 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID421176Antiviral activity against HIV isolate 584.000 063 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID1454916Aqueous solubility of the compound at pH 6.52018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID446499Oral bioavailability in rat at 5 mg/kg administered as solution in 90% PEG400/10% EtOH2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID30148The volume of distribution of compound against rat was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID443379Aqueous solubility of crystalline form of compound in buffer solution of pH 11 at 25 degC2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304720Antiviral activity against HIV1 pseudovirus in U87 cells expressing CD4 and CCR5 after 72 hrs by M33 pseudotyped assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID1299889Inhibition of HIV1 YU2 gp120-induced cell-cell fusion between viral envelope expressing African green monkey COS cells to CCR5 receptor expressing human TZM-bl cells after overnight incubation by Bright-Glo luciferase assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.
AID446484Lipophilicity, log D at pH 6.52009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID1299893Inhibition of BMS-806 resistant HIV1 YU2 gp120 T198P mutant-induced cell-cell fusion between viral envelope expressing African green monkey COS cells to CCR5 receptor expressing human TZM-bl cells at 5 uM after overnight incubation by Bright-Glo luciferas2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.
AID446495Oral bioavailability in monkey at 5 mg/kg2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304722Antiviral activity against HIV 584.000220 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID446482Cytotoxicity against human MT2 cells after 3 days by XTT assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304728Antiviral activity against HIV 589.000016 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID421181Antiviral activity against HIV isolate 589.000 033 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID1299894Inhibition of HIV1 8X gp120-induced cell-cell fusion between viral envelope expressing African green monkey COS cells and human TZM-bl cells up to 5 uM after overnight incubation by Bright-Glo luciferase assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.
AID209542Cytotoxicity activity of compound in MT-2 cells against TLAV (dual) virus that utilizes both CXR4 and CCR5 co-receptor virus was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID446480Inhibition of HIV1 LAI gp120/CD4 interaction in human HeLa67 cells assessed as inhibition of viral entry after 3 days by luciferase reporter gene assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304727Antiviral activity against HIV 589.000033 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID421175Antiviral activity against HIV isolate 584.000 060 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID304731Antiviral activity against HIV 584.000058 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID421179Antiviral activity against HIV isolate 584.000 220 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID725039Cytotoxicity against human HeLa cells expressing CD4, CCR5 after 3 days2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
AID304721Cytotoxicity against human U87 cells expressing CD4 and CXCR42007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID41206Cytotoxicity activity of compound in PM1 cells against BAl (M) Macrophage tropic virus that utilizes the CCR5 virus was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID144553Inhibitory activity of compound against NL4-3 (T) tropic virus that utilizes the CXCR-4 co-receptor was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID1442802Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral entry treated 2 to 4 hrs post infection measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID421182Antiviral activity against HIV isolate 584.000 058 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID446492Aqueous solubility of crystalline form of compound in buffer solution of pH 6.5 at 25 degC2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID304724Antiviral activity against HIV 208.000923 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID29660Oral bioavailability after paroral administration of 3.4(mg/kg) polyethelene glycol in dog was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID421177Antiviral activity against HIV isolate 584.000 066 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID725037Oral bioavailability in rat at 5 mg/kg2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
AID1442774Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral entry treated 1 hr post infection measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1295692Inhibition of CD4 (unknown origin) assessed as suppression of maximal CD4 binding to immobilized HIV-1 gp120 by ELISA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
AID446483Permeability across human Caco-2 cell membrane at pH 6.52009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID446481Metabolic stability in human liver microsomes assessed as half life2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID446487Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID23936The total clearance time in monkey was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID421171Antiviral activity against HIV isolate 584.000 017 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID1454923Competitive inhibition of soluble CD4 binding to HIV-1 gp120 after 2 hrs by ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID421180Antiviral activity against HIV isolate 584.000 227 by replication assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID446489Inhibition of recombinant CYP2D62009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID23937The total clearance time in rat was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID1525493Inhibition of HIV1 JRFL gp120 assessed as reduction in CD4/gp 120 complex formation incubated for 1 hr by ELISA2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Overview of Recent Strategic Advances in Medicinal Chemistry.
AID304723Antiviral activity against HIV 584.000063P1B by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID304726Antiviral activity against HIV 589.000821 by viral replication assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
AID446486Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID94578Inhibitory activity of compound against JRFL (M) Macrophage tropic virus that utilizes the CCR5 was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID427793Inhibition of HIV1 (isolate YU2) envelope glycoprotein 120-mediated membrane fusion between virus-transfected african green monkey COS cells and human TZM-bl cells by luciferase-based cell-cell fusion assay in absence of IC95642008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
AID29805Oral bioavailability after paroral administration of 5(mg/kg) polyethelene glycol in rat was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID41207Inhibitory activity of compound against BAl (M) Macrophage tropic virus that utilizes the CCR5 co-receptor was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID446497AUC in rat at 5 mg/kg, po2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID1241754Antiviral activity against HIV12015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID421169Inhibition of HIV1 3B recombinant gp120/sCD4 binding interaction by ELISA2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Heterobiaryl human immunodeficiency virus entry inhibitors.
AID446493Inhibition of human ERG by channel flux assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID725036Clearance in rat at 1 mg/kg, iv2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.
AID1454915Protein binding in human plasma2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID30149The volume of distribution of compound was determined in dog2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID446491Inhibition of recombinant CYP1A22009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID443378Aqueous solubility of crystalline form of compound in buffer solution of pH 2.1 at 25 degC2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID446485Antiviral activity against HIV1 clinical isolates2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
AID28505The maximum plasma concentration of compound after paroral administration of 3.4(mg/kg) polyethelene glycol in dog was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID29661Oral bioavailability after paroral administration of 3.4(mg/kg) polyethelene glycol in monkey was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's26 (57.78)29.6817
2010's14 (31.11)24.3611
2020's5 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.82 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (17.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (82.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]